{
    "organizations": [],
    "uuid": "1dd6c0d786f166846ae298553f5e2786a1544fb0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oncomed-q4-earnings-per-share-025/brief-oncomed-q4-earnings-per-share-0-25-idUSASB0C9KW",
    "ord_in_thread": 0,
    "title": "BRIEF-OncoMed Q4 Earnings Per Share $0.25",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - OncoMed Pharmaceuticals Inc:\n* ONCOMED ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS\n* Q4 REVENUE $20.6 MILLION VERSUS $6.2 MILLION * CURRENT CASH IS ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 OF 2019\n* Q4 EARNINGS PER SHARE VIEW $-0.33, REVENUE VIEW $5.2 MILLION â€” THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-09T05:32:00.000+02:00",
    "crawled": "2018-03-09T14:21:44.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "oncomed",
        "pharmaceutical",
        "inc",
        "oncomed",
        "announces",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "operational",
        "highlight",
        "q4",
        "revenue",
        "million",
        "versus",
        "million",
        "current",
        "cash",
        "estimated",
        "sufficient",
        "fund",
        "operation",
        "least",
        "q3",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}